19 July 2018 - - Elk Grove Village, Illinois-based oncology drug development company RiMO Therapeutics Inc., a pioneer in Radio-immuno Metal-Organic technology-based cancer immunotherapy, has dosed the first patient in a Phase 1 study of RiMO-301 in patients with advanced tumors, the company said.
RiMO-301 enhances the efficacy of X-ray radiotherapy via the radiotherapy-radiodynamic therapy (RT-RDT) mode of action.
The Phase 1 study is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. The primary objectives in the study include determining maximum tolerated dose, pharmacokinetics and preliminary anti-tumor activity of RiMO-301.
Privately held RiMO Therapeutics aims to address unmet medical needs and improve patient care. Its nMOF technology is in-licensed from the University of Chicago with worldwide rights in development and commercialisation.